Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Sibeprenlimab PK/PD in Chinese Healthy Subjects
NCT07105124Phase 1Completed
- Sponsor
- Otsuka Holdings
- Start
- Oct 2022
- Primary completion
- Feb 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sibeprenlimab in immunoglobulin A nephropathy (IgAN) (3 arms), sponsored by Otsuka Holdings. Primary endpoint: Sibeprenlimab serum concentrations at Week 12. Started Oct 2022; status: completed.
02
Drugs
sibeprenlimab
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07105124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07105124.